Gilead Sciences Inc (GILD)
64.78
-0.55
(-0.84%)
USD |
NASDAQ |
May 03, 16:00
64.79
+0.01
(+0.02%)
Pre-Market: 20:00
Gilead Sciences Cash from Financing (Quarterly): -1.361B for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -1.361B |
December 31, 2023 | -1.099B |
September 30, 2023 | -1.519B |
June 30, 2023 | -1.101B |
March 31, 2023 | -1.406B |
December 31, 2022 | -1.554B |
September 30, 2022 | -2.118B |
June 30, 2022 | -1.003B |
March 31, 2022 | -1.794B |
December 31, 2021 | -1.942B |
September 30, 2021 | -3.527B |
June 30, 2021 | -931.00M |
March 31, 2021 | -2.477B |
December 31, 2020 | 131.00M |
September 30, 2020 | 4.124B |
June 30, 2020 | -874.00M |
March 31, 2020 | -2.611B |
December 31, 2019 | -896.00M |
September 30, 2019 | -2.515B |
June 30, 2019 | -1.857B |
March 31, 2019 | -2.366B |
December 31, 2018 | -1.67B |
September 30, 2018 | -2.901B |
June 30, 2018 | -1.152B |
March 31, 2018 | -6.595B |
Date | Value |
---|---|
December 31, 2017 | 3.347B |
September 30, 2017 | 2.17B |
June 30, 2017 | -880.00M |
March 31, 2017 | -1.244B |
December 31, 2016 | -2.348B |
September 30, 2016 | 2.797B |
June 30, 2016 | -1.561B |
March 31, 2016 | -8.613B |
December 31, 2015 | -4.465B |
September 30, 2015 | 6.644B |
June 30, 2015 | -5.341B |
March 31, 2015 | -2.722B |
December 31, 2014 | 1.234B |
September 30, 2014 | -5.772B |
June 30, 2014 | -1.371B |
March 31, 2014 | 2.884B |
December 31, 2013 | -845.12M |
September 30, 2013 | -942.23M |
June 30, 2013 | -557.65M |
March 31, 2013 | -199.00M |
December 31, 2012 | -510.20M |
September 30, 2012 | -307.51M |
June 30, 2012 | -474.88M |
March 31, 2012 | 1.856B |
December 31, 2011 | 3.527B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.527B
Minimum
Sep 2021
4.124B
Maximum
Sep 2020
-1.316B
Average
-1.462B
Median
Cash from Financing (Quarterly) Benchmarks
Amgen Inc | -1.708B |
CymaBay Therapeutics Inc (DELISTED) | 2.729M |
Bristol-Myers Squibb Co | 14.64B |
Eli Lilly and Co | -311.30M |
Xilio Therapeutics Inc | -1.634M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 2.219B |
Cash from Investing (Quarterly) | -2.207B |
Free Cash Flow | 8.481B |
Free Cash Flow Per Share (Quarterly) | 1.780 |
Free Cash Flow to Equity (Quarterly) | 27.21B |
Free Cash Flow to Firm (Quarterly) | 2.455B |
Free Cash Flow Yield | 10.44% |